Existing vaccines will be less effective at tackling Omicron than earlier strains of Covid-19 and it may take months before pharmaceutical companies can manufacture new variant-specific jabs at scale, Moderna Chief Executive Stephane Bancel said in an interview with the Financial Times. Shares of Moderna (Nasdaq: MRNA US) have surged 38% since last Friday, but the latest comments of company’s CEO created a negative investment sentiment across markets.